Paul Clancy

Track

Insider profile

Currently holds positions in Agios Pharmaceuticals, Inc. and Incyte Corp

Performance

Overall performance
0.7
Performance over holding periods
0.7
30 days 90 days 120 days
Average return -3% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Agios Pharmaceuticals, Inc. Sept. 24, 2013 -
Independent Director Incyte Corp Jan. 20, 2015 -
Chief Financial Officer, Executive Vice President Alexion Pharmaceuticals Inc July 31, 2017 - Sept. 17, 2019
Chief Financial Officer, Executive Vice President - Finance Biogen Inc Aug. 13, 2007 - June 30, 2017
Paul Clancy's trades of Incyte Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Incyte Corp (INCY)
Transaction date
Sale
Price
119.41
Quantity 71,569 -44.2%
Value US$4,336,826
US Incyte Corp (INCY)
Transaction date
Sale
Price
364.80
Quantity 39,611 -16.5%
Value US$1,074,681
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
474.20
Quantity 83,326
Value US$1,175,812
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-19
US Incyte Corp (INCY)
S Sale
71,569 -44.2%
119.41
US$4,336,826 		71,569 -44.2% 119.41 US$4,336,826
2026-05-21 2026-05-19
US Incyte Corp (INCY)
S Sale
39,611 -16.5%
364.80
US$1,074,681 		39,611 -16.5% 364.80 US$1,074,681
2026-05-19 2026-05-19
US Incyte Corp (INCY)
PrS Proposed sale
83,326
474.20
US$1,175,812 		83,326 474.20 US$1,175,812
2018-02-08 2018-02-08
S Sale
6,079 -6.4%
116.31
US$707,048 		6,079 -6.4% 116.31 US$707,048